

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 12, 2025

Consolidated Financial Results for the Six Months Ended September 30, 2025 (Under Japanese GAAP)

Company name: TOHO HOLDINGS CO., LTD.
 Listing: Tokyo Stock Exchange
 Securities code: 8129
 URL: <https://www.tohohd.co.jp/en/>
 Representative: Hiromi Edahiro / Representative Director, President and CEO
 Inquiries: Makoto Kawamura / Executive Corporate Officer and General Manager, Corporate Strategy Division
 Telephone: +81-3-6838-2803
 Scheduled date to file semi-annual securities report: November 14, 2025
 Scheduled date to commence dividend payments: December 1, 2025
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes (for Institutional Investors and Analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the six months ended September 30, 2025 (from April 1, 2025 to September 30, 2025)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Six months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2025	767,899	1.7	7,258	-1.7	8,329	-3.1	6,244	16.0
September 30, 2024	754,974	2.7	7,380	13.7	8,596	8.2	5,383	-38.7

Note: Comprehensive income For the six months ended September 30, 2025: ¥7,405 million [-7.8%]
 For the six months ended September 30, 2024: ¥8,035 million [-13.1%]

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
September 30, 2025	99.12	92.72
September 30, 2024	85.71	75.64

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Millions of yen	Millions of yen	%
September 30, 2025	754,857	266,975	35.3
March 31, 2025	722,805	256,897	35.5

Reference: Equity As of September 30, 2025: ¥266,726 million
 As of March 31, 2025: ¥256,654 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	—	25.00	—	40.00	65.00
Fiscal year ending March 31, 2026	—	45.00			
Fiscal year ending March 31, 2026 (Forecast)			—	45.00	90.00

Note: Revision to the forecast of cash dividends most recently announced: None

3. Consolidated financial forecast for fiscal year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Percentages indicate the rate of change compared with the preceding fiscal year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Net income per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	1,572,000	3.5	20,700	9.3	22,600	9.1	15,700	-20.9	245.59

Note: Revision of consolidated financial forecast most recently announced: None

* Notes

(1) Significant changes in the scope of consolidation during the period: Yes

Newly included: 1 company (K-CREATE Inc.)

Excluded: —

(2) Adoption of accounting treatment specific to the preparation of semi-annual consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of September 30, 2025	73,025,942 shares
As of March 31, 2025	73,025,942 shares

(ii) Number of treasury shares at the end of the period

As of September 30, 2025	7,604,819 shares
As of March 31, 2025	10,422,804 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Six months ended September 30, 2025	63,002,269 shares
Six months ended September 30, 2024	62,815,614 shares

* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.

* Proper use of earnings forecasts, and other special matters

Any forward-looking statements contained in this report, including performance projections, are based on information currently available to the Company as well as certain assumptions that the Company determined to be rational at the time of the release of this report, and it is not intended that the Company undertake to achieve such results. Actual results may differ significantly from the projections above, due to a variety of factors.

Please refer to Explanation of Projections of Consolidated Operating Results for Fiscal Year ending March 31, 2026 on page 4 of this report (the attached document) for the suppositions on which the performance projections are based and points that have to be borne in mind for the use of such projections.

○Contents of Attached Document

1. Qualitative Information on Financial Results for the Six Months Ended September 30, 2025	2
(1) Explanation of Management Results	2
(2) Explanation of Financial Position	4
(3) Explanation of Projections of Consolidated Operating Results for Fiscal Year ending March 31, 2026	4
2. Semi-annual Consolidated Financial Statements and Main Notes	5
(1) Semi-annual Consolidated Balance Sheets	5
(2) Semi-annual Consolidated Statement of Income and Semi-annual Consolidated Statement of Comprehensive Income	7
Semi-annual Consolidated Statement of Income	7
Semi-annual Consolidated Statement of Comprehensive Income	9
(3) Semi-annual Consolidated Statement of Cash Flows	10
(4) Notes Concerning Semi-annual Consolidated Financial Statements	12
(Notes Concerning Premise of a Going Business)	12
(Notes Concerning Material Changes in Shareholders' Equity)	12
(Segmental Information)	13

1. Qualitative Information on Financial Results for the Six Months Ended September 30, 2025

(1) Explanation of Management Results

In the pharmaceutical industry, the interim-period NHI drug price revisions were implemented in April for 53% of all products. In addition, special measures were applied to recalculate unprofitable products and minimum NHI drug prices raised. Furthermore, with the amendment of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices in May, deregulation of over-the-counter drug sales, reinforcement of the stable supply system for prescription pharmaceuticals, and enhancement of pharmacy functions, including partial outsourcing of dispensing operations, will be implemented in a phased manner starting November 2025. This is expected to further accelerate the transformation of healthcare delivery systems and pharmaceutical distribution. In the six months ended September 30, 2025, the prescription pharmaceuticals market grew faster than in the corresponding period of the previous year thanks to robust sales of cancer drugs, specialty pharmaceuticals and vaccines, such as herpes zoster vaccine, despite a decrease in sales of COVID 19-related products.

Under these circumstances, the Group has been promoting measures to improve profitability and productivity in its core pharmaceutical wholesaling business in accordance with the action plan announced last November for the final year of the Medium-Term Management Plan 2023-2025 “Create the Next Generation.”

With regard to business transformation, our pharmaceutical MSs (Marketing Specialists) were focusing on developing the reagents market through the integration of pharmaceutical and reagent operations. Moreover, toward the shift to the Team System, which is targeted to start in April 2026, we worked on personnel deployment as well as the introduction of new delivery terminals and Delivery Management System with a view to separating commercial transactions and physical distribution.

As for specialty products, which are expected to grow in the future, we are continuing to expand the functions of our full-line services, which provide a range of services from product R&D to manufacturing and distribution, for pharmaceutical manufacturers in Japan and abroad. In July, the Group entered into a business alliance with TEIJIN REGENET CO., LTD. and ITOCHU Corporation to begin building a regenerative medical ecosystem in which the three companies will collaborate to provide one-stop support services necessary for the launch of regenerative medical products. As the first step, we jointly held the Regenerative Medical Top Runner Seminar in September, targeting pharmaceutical manufacturers and drug discovery ventures.

In the customer support business, we actively worked to offer cloud-based picking audit system EveryPick provided by PHARUMO, Inc., with which we formed a capital and business alliance in June. Additionally, we are collaborating on the new pharmacy DX platform service N-Bridge and the prescription information transmission terminal NB Station, which are being developed by PHARUMO, Inc. and the Japan Pharmaceutical Association. Specifically, we are providing technology from the Group's prescription transmission system ENI Pharmacy, which has a proven track record of implementation in numerous medical institutions, to contribute to the continuous functional improvement of the N-Bridge service and its widespread use nationwide.

Furthermore, as part of its growth strategy, the Company established a corporate venture capital (CVC) fund TOHO Ventures, with Global Brain Corporation, an independent venture capital firm, as a general partner, with the aim of accelerating open innovation and creating new businesses that will lead the next generation, in addition to strengthening existing businesses. The fund plans to invest mainly in advanced overseas startups in the fields of drug discovery and biotechnology and medical DX. Going forward, we will actively leverage the Group's existing assets and operate the funds as a co-creation type CVC to realize the commercialization and social implementation of investee companies' businesses. For details, please refer to "Notice Regarding Establishment of CVC Fund" announced today.

As for sustainability management, we are promoting human capital management. We started in July a new town-hall meeting as a forum for management to directly communicate with employees.

To further strengthen governance, we established in August 2024 the Governance Enhancement Special Committee as an advisory body to the Board of Directors, consisting of members independent from the Company with expertise in law, finance, corporate management, and other relevant fields. The committee held discussions until October 2025 on the Group's overall governance issues, including compliance and risk management, and improvement measures from an objective and professional perspective. At its meeting on October 9, 2025, the Company's Board of Directors received from the Governance Enhancement Special Committee the Final Report of the Governance Enhancement Special Committee: Report on Strengthening the Governance Systems and Improving Operations. On October 31, the Company publicly announced the full text of the report and a summary of the recommendations laid out in the report, as well as the Company's basic policy and specific action policies for responding to the recommendations. We will strive to further strengthen our governance by steadily implementing initiatives in accordance with these policies.

The Company's consolidated operating results for the six months ended September 30, 2025 recorded 767,899 million yen for net sales (an increase of 1.7% on a year-on-year basis), 7,258 million yen for operating profit (a decrease of 1.7% on a year-on-year basis), 8,329 million yen for ordinary profit (a decrease of 3.1% on a year-on-year basis), and 6,244 million yen for profit attributable to owners of parent (an increase of 16.0% on a year-on-

year basis).

The outline of business segment operating results are as follows.

< Pharmaceutical wholesaling business >

While there was a decline in demand for COVID-19 drugs, reagents, and vaccines, sales of specialty pharmaceuticals and other limited-handling products for selected wholesalers remained strong. In addition, we conducted price negotiations in line with the Ministry of Health, Labour and Welfare's Guidelines for the Improvement of Commercial Transaction Practices of Ethical Drugs for Manufacturers, Wholesalers, and Medical Institutions / Pharmacies, and worked to visualize and optimize distribution costs for each product and customer. In the customer support business, we released the standard and professional versions of the HeLios cloud, which enhances the convenience of the HeLios medical appointment system. For existing products, we focused on high-value-added products, efficiently allocated resources, strengthened alliances, and nurtured human resources to improve our proposal capabilities.

As a result, the pharmaceutical wholesaling business posted net sales of 739,165 million yen (an increase of 1.4% on a year-on-year basis) and segment profit (operating profit) of 7,349 million yen (a decrease of 8.2% on a year-on-year basis) for the six months ended September 30, 2025 under review.

< Dispensing pharmacy business >

To implement the transformation of the dispensing pharmacy business, a key measure of the Medium-Term Management Plan, we worked to reorganize our operating companies and reduced the number of dispensing pharmacy operating companies under PHARMA CLUSTER CO., LTD. from 24 at the end of March 2024 to nine by October 1 this year. We also made progress in responding to the revisions to dispensing fees, obtained additional benefits for the development of a medical DX promotion system utilizing the Myna Health Insurance Card, and worked on home-based medical care. Furthermore, to save labor and enhance pharmacists' patient-facing duties, we established a new prescription input center in July this year and began accepting prescription input requests from stores.

As a result, in the six months ended September 30, 2025, net sales were 49,542 million yen (an increase of 5.2% year on year) and segment profit (operating profit) was 600 million yen.

< Pharmaceutical manufacturing and sales business >

We have been engaged in the stable supply of high-quality and high value-added pharmaceuticals by strictly monitoring the quality of products based on our own verification system and establishing a planned production and procurement system. In addition, in the same facility as TBC DynaBASE, we opened the Haneda Packaging Center, a secondary packaging facility for prescription pharmaceuticals that can conduct inspection, packaging, and storage of mainly vial products containing cryogenic and antibody drugs. We are preparing to start accepting orders in the latter half of this fiscal year.

In the six months ended September 30, 2025, net sales amounted to 5,747 million yen (an increase of 2.8% year on year) with segment profit (operating profit) of 120 million yen (a decrease of 72.9% year on year), mainly due to increased cost of sales and delays in shipping some contracted products.

< Other peripheral businesses >

In the six months ended September 30, 2025, net sales amounted to 3,590 million yen (an increase of 11.9% on a year-on-year basis.) and segment profit (operating profit) was 475 million yen (an increase of 134.0 % on a year-on-year basis.).

(Note) Segment sales include inter-segment transactions.

(2) Explanation of Financial Position

(Assets)

Current assets increased 5.9% from the end of the previous consolidated fiscal year to 581,341 million yen with an increase in cash and deposits of 9,917 million yen, and an increase in notes and accounts receivable-trade of 17,686 million yen in other.

Non-current assets decreased 0.2% from the end of the previous consolidated fiscal year to 173,516 million yen with an increase in property, plant and equipment of 1,688 million yen, and a decrease in investments and other assets of 2,079 million yen.

As a result, consolidated net assets increased 4.4% from the end of the previous consolidated fiscal year, to 754,857 million yen.

(Liabilities)

Current liabilities increased 8.6% from the end of the previous consolidated fiscal year to 460,684 million yen with an increase in notes and accounts payable-trade of 38,454 million yen in other.

Non-current liabilities decreased 35.1% from the end of the previous consolidated fiscal year to 27,198 million yen with a decrease in bonds payable of 11,246 million yen, and a decrease in provision for loss on Antimonopoly Act of 4,849 million yen in other.

As a result, total liabilities increased 4.7% from the end of the previous consolidated fiscal year, to 487,882 million yen.

(Net assets)

Total net assets increased 3.9% from the end of the previous consolidated fiscal year to 266,975 million yen with an increase in retained earnings of 3,858 million yen, and a decrease in treasury shares of 5,747 million yen in other.

(Analysis of the Cash Flow Position)

Cash and cash equivalents (hereinafter referred to as “cash”) during this consolidated first half increased 11,316 million yen from the end of the previous consolidated fiscal year. As a result, the balance at the end of this first half was 89,543 million yen (a decrease of 14,381 million yen on a year-on-year basis). The following describes the three categories of consolidated cash positions during this consolidated first half, as well as the factors responsible.

(Cash Flows from Operating Activities)

Cash flow from operating activities was an inflow of 25,616 million yen (an increase of 36,361 million yen on a year-on-year basis). Although inflow was secured by some positive factors such as income before income taxes of 9,112 million yen, depreciation of 2,899 million yen, increase in trade payables of 37,795 million yen, these were somewhat offset by negative factors including an increase in notes and accounts receivable-trade of 17,166 million yen, and income taxes paid of 5,363 million yen in other.

(Cash Flows from Investing Activities)

Cash flow from investing activities was an outflow of 2,999 million yen (an increase of 1,590 million yen from the previous fiscal year). Although inflow was secured by some positive factors such as proceeds from withdrawal of time deposits of 3,986 million yen, these were somewhat offset by negative factors including payments into time deposits of 1,970 million yen, purchase of property, plant and equipment of 3,540 million yen, purchase of investment securities of 2,474 million yen in other.

(Cash Flows from Financing Activities)

Cash flow from financing activities was an outflow of 12,582 million yen (a decrease of 2,395 million yen on a year-on-year basis), which is mainly attributable to purchase of treasury shares of 6,202 million yen, and increase in deposits for purchase of treasury shares of 3,844 million yen, and dividends paid of 2,504 million yen in other.

(3) Explanation of Projections of Consolidated Operating Results for Fiscal Year ending March 31, 2026

There are no changes in the projected consolidated results of the full-term of the fiscal year ending March 31, 2026 published on May 14, 2025.

2. Semi-annual Consolidated Financial Statements and Main Notes

(1) Semi-annual Consolidated Balance Sheet

(Unit: million yen)

	As of March 31, 2025	As of September 30, 2025
Assets		
Current assets		
Cash and deposits	86,533	96,450
Notes and accounts receivable-trade	332,491	350,178
Merchandise and finished goods	90,787	91,870
Raw materials and supplies	207	209
Other	39,312	42,922
Allowance for doubtful accounts	-385	-290
Total current assets	548,946	581,341
Non-current assets		
Property, plant and equipment	86,844	88,533
Intangible assets		
Goodwill	193	137
Other	5,893	5,997
Total intangible assets	6,087	6,135
Investments and other assets		
Other	82,468	80,280
Allowance for doubtful accounts	-1,541	-1,432
Total investments and other assets	80,927	78,847
Total non-current assets	173,858	173,516
Total assets	722,805	754,857

	As of March 31, 2025	As of September 30, 2025
Liabilities		
Current liabilities		
Notes and accounts payable-trade	397,722	436,177
Short-term borrowings	1,717	1,670
Income taxes payable	5,879	2,480
Provision for bonuses	3,583	3,627
Provision for bonuses for directors	42	26
Other	15,062	16,702
Total current liabilities	424,008	460,684
Non-current liabilities		
Bonds payable	13,081	1,834
Long-term borrowings	4,478	4,321
Provision for loss on guarantees	286	386
Retirement benefit liability	2,764	2,776
Asset retirement obligations	2,958	2,997
Provision for loss on Antimonopoly Act	4,849	—
Other	13,480	14,881
Total non-current liabilities	41,899	27,198
Total liabilities	465,907	487,882
Net assets		
Shareholders' equity		
Share capital	10,649	10,649
Capital surplus	45,212	44,524
Retained earnings	218,932	222,790
Treasury shares	-28,819	-23,072
Total shareholders' equity	245,975	254,892
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	15,089	16,244
Revaluation reserve for land	-4,409	-4,409
Total accumulated other comprehensive income	10,679	11,834
Share acquisition rights	126	126
Non-controlling interests	116	122
Total net assets	256,897	266,975
Total liabilities and net assets	722,805	754,857

(2) Semi-annual Consolidated Statement of Income and Semi-annual Consolidated Statement of Comprehensive Income
Semi-annual Consolidated Statement of Income

(Unit: million yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Net sales	754,974	767,899
Cost of sales	696,589	708,051
Gross profit	58,384	59,848
Selling, general and administrative expenses		
Remuneration, salaries and allowances for directors	20,445	21,226
Provision for bonuses	3,630	3,653
Provision for bonuses for directors	22	26
Retirement benefit expenses	169	247
Welfare expenses	3,947	4,096
Vehicle expenses	514	520
Provision of allowance for doubtful accounts	55	-90
Depreciation	2,632	2,673
Amortization of goodwill	93	56
Rent expenses	3,953	4,075
Taxes and dues	1,007	958
Non-deductible temporary paid consumption tax expense	3,374	3,737
Other	11,157	11,409
Total selling, general and administrative expenses	51,004	52,590
Operating profit	7,380	7,258
Non-operating income		
Interest income	59	97
Dividend income	621	574
Share of profit of entities accounted for using equity method	92	—
Rental income from real estate	406	411
Other	251	330
Total non-operating income	1,431	1,413
Non-operating expenses		
Interest expenses	22	27
Share of loss of entities accounted for using equity method	—	5
Real estate lease expenses	89	87
Provision for loss on guarantees	41	100
Other	62	123
Total non-operating expenses	215	343
Ordinary profit	8,596	8,329

(Unit: million yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Extraordinary income		
Gain on sales of non-current assets	2	457
Gain on liquidation of subsidiaries and associates	—	224
Gain on extinguishment of tie-in shares	22	—
Reversal of provision for loss on Antimonopoly Act	—	371
Other	0	53
Total extraordinary income	26	1,105
Extraordinary losses		
Loss on disposal of non-current assets	54	169
Impairment losses	18	—
Loss on valuation of investment securities	3	153
Other	5	—
Total extraordinary losses	81	322
Profit before income taxes	8,541	9,112
Income taxes-current	3,629	2,038
Income taxes-deferred	-477	822
Total income taxes	3,151	2,861
Net profit	5,390	6,250
Profit attributable to non-controlling interests	6	5
Profit attributable to owners of parent	5,383	6,244

Semi-annual Consolidated Statement of Comprehensive Income

(Unit: million yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Net profit	5,390	6,250
Other comprehensive income		
Valuation difference on available-for-sale securities	2,655	1,141
Share of other comprehensive income of entities accounted for using equity method	-11	13
Total other comprehensive income	2,644	1,155
Comprehensive income	8,035	7,405
Comprehensive income attributable to:		
Comprehensive income attributable to owners of parent	8,028	7,400
Comprehensive income attributable to non-controlling interests	6	5

(3) Semi-annual Consolidated Statement of Cash Flows

(Unit: million yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Cash flows from operating activities		
Profit before income taxes	8,541	9,112
Depreciation	2,817	2,899
Impairment losses	18	—
Amortization of goodwill	93	56
Increase (decrease) in retirement benefit liability	36	-54
Increase (decrease) in provision for bonuses	-86	24
Increase (decrease) in provision for bonuses for directors (and other officers)	-20	-16
Increase (decrease) in allowance for doubtful accounts	49	-204
Increase (decrease) in provision for loss on guarantees	41	100
Interest and dividend income	-681	-671
Interest expense	22	27
Loss (gain) on sale and retirement of non-current assets	52	-287
Loss (gain) on sales and valuation of investment securities	2	100
Decrease (increase) in trade receivables	-2,853	-17,166
Decrease (increase) in inventories	-8,167	-761
Decrease (increase) in other assets	-1,016	500
Increase (decrease) in trade payables	435	37,795
Increase (decrease) in other liabilities	-935	61
Increase (decrease) in accrued consumption taxes	-3,019	428
Other loss (gain)	-363	-523
Subtotal	-5,033	31,420
Interest and dividends received	641	638
Interest paid	-23	-27
Income taxes paid	-6,739	-5,363
Receipt of returned deposit	—	2,554
Settlement paid	—	-4,132
Other	410	525
Net cash provided by (used in) operating activities	-10,744	25,616

(Unit: million yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Cash flows from investing activities		
Payments into time deposits	-676	-1,970
Proceeds from withdrawal of time deposits	672	3,986
Purchase of property, plant and equipment	-2,241	-3,540
Proceeds from sales of property, plant and equipment	34	840
Purchase of intangible assets	-819	-696
Proceeds from sale of intangible assets	0	1
Purchase of investment securities	-1,155	-2,474
Proceeds from sales and redemption of investment securities	1	284
Purchase of shares of subsidiaries and associates	-934	—
Payments for acquisition of businesses	-33	—
Payments for asset retirement obligations	-2	-25
Loan advances	-9	-90
Proceeds from collection of loans receivable	250	70
Other	323	614
Cash flows from investing activities	-4,590	-2,999
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	-881	545
Repayments of long-term borrowings	-214	-198
Purchase of treasury shares	-2,707	-6,202
Decrease (increase) in segregated deposits for purchase of treasury shares	-4,795	-3,844
Repayments of finance lease liabilities	-207	-376
Dividends paid	-1,381	-2,504
Cash flows from financing activities	-10,187	-12,582
Net increase (decrease) in cash and cash equivalents	-25,522	10,034
Cash and cash equivalents at beginning of period	128,673	78,226
Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries	774	515
Increase (decrease) in cash and cash equivalents resulting from change in scope of consolidation	—	767
Cash and cash equivalents at the end of period	103,925	89,543

(4) Notes Concerning Semi-annual Consolidated Financial Statements
(Notes Concerning Premise of a Going Business)
Not applicable.

(Notes Concerning Material Changes in Shareholders' Equity)
Not applicable.

(Segmental Information)

I Six months ended September 30, 2024

1. Information about sales and profit or loss by reportable segment

	Reportable segments					Adjustments (million yen) (Note 1)	Amount on semi-annual consolidated statement of income (million yen) (Note2)
	Pharmaceutical Wholesaling (million yen)	Dispensing Pharmacy (million yen)	Pharmaceutical Manufacturing and Sales (million yen)	Other Peripheral Businesses (million yen)	Total (million yen)		
Net Sales							
(1) Sales to external customers	704,284	47,092	1,382	2,214	754,974	—	754,974
(2) Inter-segment sales	24,448	19	4,209	994	29,672	-29,672	—
Total	728,733	47,111	5,592	3,209	784,646	-29,672	754,974
Segment profit	8,005	-18	442	203	8,633	-1,252	7,380

(Note) 1. The amount of the adjustments for segment profits or losses shows the elimination of internal transactions and unrealized profit and corporate expenses not attributable to any reportable segment.

2. The amounts for profit or losses in the reportable segments were subsequently adjusted with the amount of operating profit on the semi-annual consolidated statement of income.

2. Information about impairment losses on noncurrent assets or goodwill by each business segment

Not applicable.

II Six months ended September 30, 2025

1. Information about sales and profit or loss by reportable segment

	Reportable segments					Adjustments (million yen) (Note 1)	Amount on semi-annual consolidated statement of income (million yen) (Note2)
	Pharmaceutical Wholesaling (million yen)	Dispensing Pharmacy (million yen)	Pharmaceutical Manufacturing and Sales (million yen)	Other Peripheral Businesses (million yen)	Total (million yen)		
Net Sales							
(1) Sales to external customers	714,217	49,540	1,298	2,843	767,899	—	767,899
(2) Inter-segment sales	24,947	2	4,448	746	30,145	-30,145	—
Total	739,165	49,542	5,747	3,590	798,045	-30,145	767,899
Segment profit	7,349	600	120	475	8,545	-1,287	7,258

(Note) 1. The amount of the adjustments for segment profits shows the elimination of internal transactions and unrealized profit and corporate expenses not attributable to any reportable segment.

2. The amounts for profit in the reportable segments were subsequently adjusted with the amount of operating profit on the semi-annual consolidated statement of income.

2. Information about impairment losses on noncurrent assets or goodwill by each business segment

Not applicable.